Information:
Fel:
ID
28420
Beskrivning
Study part: Investigator/ Site Information (Screening). A Phase III, Multicenter, Randomized, Double-Masked, Active Treatment-Controlled Study Of The Efficacy And Safety Of rhuFab V2 (Ranibizumab) Compared With Verteporfin (Visudyne®) Photodynamic Therapy In Subjects With Predominantly Classic Subfoveal Neovascular Age-Related Macular Degeneration
Nyckelord
Versioner (1)
- 2018-01-11 2018-01-11 -
Rättsinnehavare
Roche
Uppladdad den
11 januari 2018
DOI
För en begäran logga in.
Licens
Creative Commons BY-NC 3.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Investigator/ Site Information (Screening) rhuFab V2 Neovascular Age-Related Macular Degeneration FVF2587g
Investigator/ Site Information (Screening)
- StudyEvent: ODM
Similar models
Investigator/ Site Information (Screening)
- StudyEvent: ODM
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Subject Number
Item
Subject Number:
text
C2348585 (UMLS CUI [1])
Subject Initials
Item
Subject Initials:
text
C1997894 (UMLS CUI [1,1])
C2986440 (UMLS CUI [1,2])
C2986440 (UMLS CUI [1,2])
Date of report
Item
Report Date:
date
C1302584 (UMLS CUI [1])
Investigator Number
Item
Investigator Number:
text
C2826689 (UMLS CUI [1])
Site Number
Item
Site Number:
text
C2825164 (UMLS CUI [1,1])
C0237753 (UMLS CUI [1,2])
C0237753 (UMLS CUI [1,2])